Canada markets closed

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.91+0.14 (+0.89%)
At close: 04:00PM EDT
15.91 0.00 (0.00%)
After hours: 04:02PM EDT

CareDx, Inc

8000 Marina Boulevard
South San Francisco, CA 94005
United States
415 287 2300

IndustryDiagnostics & Research
Full Time Employees635

Key Executives

NameTitlePayExercisedYear Born
Mr. Abhishek JainCFO & Principal Accounting Officer688.12kN/A1977
Dr. Peter Maag Ph.D.Executive Director54.94kN/A1967
Mr. Alexander L. JohnsonPresident of Patient & Testing Services690.85kN/A1975
Mr. John Walter Hanna Jr.President, CEO & DirectorN/AN/A1980
Ms. Marica Grskovic Ph.D.Chief Operating OfficerN/AN/AN/A
Dr. Robert N. Woodward Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerN/AN/AN/A
Mr. Jeffrey A. NovackGeneral Counsel & SecretaryN/AN/A1983
Ms. Stacey FollonSenior VP & Head of Human ResourcesN/AN/AN/A
Mr. Kashif RathoreChief of Patient & Digital SolutionsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

CareDx, Inc’s ISS Governance QualityScore as of July 1, 2024 is 6. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.